Dose-dependent effects of dexmedetomidine on POCD: mediated by perioperative neuroimmune modulation in cholecystectomy patients

Background Postoperative cognitive dysfunction (POCD) remains a major clinical challenge, and perioperative neuroinflammation has been recognized as a key contributing factor. Although our previous trial confirmed that dexmedetomidine (DEX) reduces the incidence of POCD, the precise immunomodulatory mechanism underlying its neuroprotective effect and the corresponding dose–response relationship remain to be fully elucidated. This study was designed to test the hypothesis that DEX provides dose-dependent neuroprotection by alleviating systemic inflammation and the subsequent neuroimmune responses. Methods A retrospective cohort study nested within a prospective cohort was performed based on a previous prospective cohort. Patients undergoing elective laparoscopic cholecystectomy were allocated into four groups according to DEX dose: control group (C: 0 μg/kg), low-dose group (D1: 0.4 μg/kg), medium-dose group (D2: 0.6 μg/kg), and high-dose group (D3: 0.8 μg/kg). POCD cases and non-POCD controls were matched at a 1:2 ratio for age, sex, educational level, and operative duration. Serum levels of interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), S100 calcium-binding protein β (S100β), neuron-specific enolase (NSE), and brain-derived neurotrophic factor (BDNF) were measured preoperatively, 24 h postoperatively (T1), and 48 h postoperatively (T2) using enzyme-linked immunosorbent assay (ELISA). Multivariable logistic regression and bootstrap mediation analysis were conducted. Results Among the initial cohort of 361 patients, 24 POCD cases were matched with 48 control subjects. There were no significant differences in preoperative biomarker levels between groups. At 24 and 48 h postoperatively, serum levels of IL-6, TNF-α, NSE, and S100β were significantly reduced in a DEX dose-dependent manner ( p < 0.01), whereas BDNF levels were significantly elevated ( p < 0.01). The high-dose DEX group showed the most significant changes, with biomarker levels significantly different from those in the control and low-dose groups ( p < 0.05). Multivariable regression confirmed that high-dose DEX was an independent protective factor against POCD (OR: 0.82 per 0.1 μg/kg; 95% CI: 0.74–0.91; p < 0.001). Mediation analysis revealed that the protective effect of DEX against POCD was mediated by inhibiting early postoperative IL-6 release. Conclusion This study demonstrates that DEX significantly reduces neuroinflammation and the incidence of POCD in a dose-dependent manner after laparoscopic cholecystectomy. The neuroprotective effect of DEX is mainly mediated by suppressing IL-6 release, indicating that inhibition of this key proinflammatory cytokine represents a critical mechanism underlying the beneficial effects of DEX. A DEX dose of 0.6 μg/kg or higher is recommended for optimal neuroprotection.

Authors

Institutions

Publication Details

Journal
Frontiers in Aging Neuroscience
Published
2026-11-13
DOI
https://doi.org/10.3389/fnagi.2026.1807418
Primary Topic
Intensive Care Unit Cognitive Disorders
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Dose-dependent effects of dexmedetomidine on POCD: mediated by perioperative neuroimmune modulation in cholecystectomy patients

Yanlong Fu, Wenxin Shi, Zhiyong Song, Huiru Chen et al.
1 links
Frontiers in Aging Neuroscience
Intensive Care Unit Cognitive Disorders
article

Dose-dependent effects of dexmedetomidine on POCD: mediated by perioperative neuroimmune modulation in cholecystectomy patients

Yanlong Fu, Wenxin Shi, Zhiyong Song, Huiru Chen, Taiyi Fan, Qiang Wei
article en

Abstract

Background Postoperative cognitive dysfunction (POCD) remains a major clinical challenge, and perioperative neuroinflammation has been recognized as a key contributing factor. Although our previous trial confirmed that dexmedetomidine (DEX) reduces the incidence of POCD, the precise immunomodulatory mechanism underlying its neuroprotective effect and the corresponding dose–response relationship remain to be fully elucidated. This study was designed to test the hypothesis that DEX provides dose-dependent neuroprotection by alleviating systemic inflammation and the subsequent neuroimmune responses. Methods A retrospective cohort study nested within a prospective cohort was performed based on a previous prospective cohort. Patients undergoing elective laparoscopic cholecystectomy were allocated into four groups according to DEX dose: control group (C: 0 μg/kg), low-dose group (D1: 0.4 μg/kg), medium-dose group (D2: 0.6 μg/kg), and high-dose group (D3: 0.8 μg/kg). POCD cases and non-POCD controls were matched at a 1:2 ratio for age, sex, educational level, and operative duration. Serum levels of interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), S100 calcium-binding protein β (S100β), neuron-specific enolase (NSE), and brain-derived neurotrophic factor (BDNF) were measured preoperatively, 24 h postoperatively (T1), and 48 h postoperatively (T2) using enzyme-linked immunosorbent assay (ELISA). Multivariable logistic regression and bootstrap mediation analysis were conducted. Results Among the initial cohort of 361 patients, 24 POCD cases were matched with 48 control subjects. There were no significant differences in preoperative biomarker levels between groups. At 24 and 48 h postoperatively, serum levels of IL-6, TNF-α, NSE, and S100β were significantly reduced in a DEX dose-dependent manner ( p < 0.01), whereas BDNF levels were significantly elevated ( p < 0.01). The high-dose DEX group showed the most significant changes, with biomarker levels significantly different from those in the control and low-dose groups ( p < 0.05). Multivariable regression confirmed that high-dose DEX was an independent protective factor against POCD (OR: 0.82 per 0.1 μg/kg; 95% CI: 0.74–0.91; p < 0.001). Mediation analysis revealed that the protective effect of DEX against POCD was mediated by inhibiting early postoperative IL-6 release. Conclusion This study demonstrates that DEX significantly reduces neuroinflammation and the incidence of POCD in a dose-dependent manner after laparoscopic cholecystectomy. The neuroprotective effect of DEX is mainly mediated by suppressing IL-6 release, indicating that inhibition of this key proinflammatory cytokine represents a critical mechanism underlying the beneficial effects of DEX. A DEX dose of 0.6 μg/kg or higher is recommended for optimal neuroprotection.

Frontiers in Aging NeuroscienceVol. 18
North China University of Science and Technology (CN), Second Hospital of Hebei Medical University (CN), Bethune International Peace Hospital (CN)
Good health and well-being
Intensive Care Unit Cognitive Disorders
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon